1-4 of 4
Toshihiko Kitahara
Close
Sort by
Journal Articles

Daprodustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, Improves Hematological Insufficiency without Progression of Myelodysplastic Syndrome with Chronic Kidney Disease

Ryujiro Hara, Toshihiko Kitahara, Hiroki Numata, Shigeki Watanabe, Eri Kikkawa, Makoto Onizuka, Hiroshi Kawada
Journal: Blood
Blood (2023) 142 (Supplement 1): 6495.
https://doi.org/10.1182/blood-2023-182991
Published: 2023
Journal Articles

Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3985.
https://doi.org/10.1182/blood.V122.21.3985.3985
Published: 2013
Journal Articles

Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Seiichiro Katagiri, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3840.
https://doi.org/10.1182/blood.V122.21.3840.3840
Published: 2013
Journal Articles

Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells

Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Seiichiro Katagiri, Toshihiko Kitahara, Kazuma Ohyashiki
Journal: Blood
Blood (2013) 122 (17): 3086–3088.
https://doi.org/10.1182/blood-2013-04-494773
Published: 2013